OTC · VICA
Rafina Innovations Inc.
$0.00$0.00 (0.0%)
Rafina Innovations Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.67% below the high.
Loading market information…
OTC · VIVE · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Viveve Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Viveve Medical, Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.51. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Viveve Medical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Viveve develops and sells healthcare-focused human resources (HR) software solutions designed to streamline and unify HR operations for healthcare organizations. It offers an all-in-one platform that supports recruitment, employee management, and attendance management, aiming to reduce administrative burden and enhance the employee experience throughout their career lifecycle. The company also provides solutions specifically tailored for the healthcare and mental and behavioral health sectors. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:22 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2021 | May 13, 2021 | -$0.80-56.86% vs estimate | $1.45M+40.5% vs estimate |
|---|
| Q4 2020 | Mar 18, 2021 | -$1.85+28.57% vs estimate | $1.95M |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
Rafina Innovations Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.67% below the high.
$0.00+$0.00 (0.0%)
Caliber Imaging & Diagnostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.5% below the high.
$0.00$0.00 (0.0%)
Sunridge International, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.49% below the high.
$0.00$0.00 (0.0%)
SpectraScience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.0% below the high.
$0.00$0.00 (0.0%)
Baudax Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Kaleido Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.95% below the high.
$0.00$0.00 (0.0%)
Nemaura Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00-$0.00 (-33.33%)
UpHealth, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
